ARCT Company Profile and Key Details

Q: Who are the executives of ARCT?

Mr. Keith C. Kummerfeld CPASenior Vice President of Fin. & Corporation ControllerMr. Keith C. Kummerfeld C.P.A.Senior Vice President of Fin. & Corporation ControllerMs. Neda SafarzadehVice President and Head of IR/PR & MarketingMr. Andrew H. Sassine MBAChief Financial Officer & DirectorMr. Lance KurataChief Legal OfficerMr. Deepankar RoySenior Director of Investor RelationsDr. Padmanabh ChivukulaFounder, Chief Scientific Officer, Chief Operating Officer & Sec.Mr. Kevin T. SkolChief Bus. OfficerDr. Dushyant B. Varshney Ph.D.Chief Technology OfficerKyle GutstadtSenior Analyst of Investor & PRDr. Juergen Froehlich FCPh, M.D., MBAChief Medical OfficerDr. Igor Smolenov M.D., Ph.D.Chief Devel. OfficerDr. Steven George Hughes M.B.A., M.D.Chief Medical OfficerMr. Joseph E. Payne M.Sc.Founder, Pres, Chief Executive Officer & Director

NASDAQ : ARCT

Arcturus Therapeutics

$7.10

-0.19-2.61%

At Close 4:00 PM

68.71

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Arcturus Therapeutics Holdings Inc. (ARCT) stock surged +2.39%, trading at $7.27 on NASDAQ, up from the previous close of $7.10. The stock opened at $7.03, fluctuating between $7.00 and $7.35 in the recent session.

Stock Snapshot

7.1

Prev. Close

206.57M

Market Cap

Day Low

-2.96

P/E Ratio

-2.46

EPS (TTM)

-0.78

Cash Flow per Share

7.03

Open

28.41M

Number of Shares

7.3499

Day High

92.13%

Free Float in %

10.46

Book Value

342.66K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 20, 2026	7.01	7.28	6.95	7.10	497.69K
Jan 16, 2026	7.60	7.74	7.29	7.29	413.19K
Jan 15, 2026	7.78	7.82	7.45	7.61	418.34K
Jan 14, 2026	7.56	7.79	7.42	7.73	626.63K
Jan 13, 2026	7.61	7.93	7.48	7.57	919.65K
Jan 12, 2026	7.08	7.57	6.91	7.53	1.05M
Jan 09, 2026	6.85	6.97	6.70	6.78	352.12K
Jan 08, 2026	6.74	6.87	6.63	6.77	443.83K
Jan 07, 2026	6.65	6.99	6.65	6.84	524.71K
Jan 06, 2026	6.26	6.69	6.26	6.61	457.14K
Jan 05, 2026	6.34	6.40	6.13	6.37	488.68K
Jan 02, 2026	6.19	6.33	6.11	6.25	424.22K
Dec 31, 2025	6.10	6.17	6.02	6.13	634.16K
Dec 30, 2025	6.14	6.28	6.09	6.19	442.44K
Dec 29, 2025	6.13	6.29	6.07	6.16	590.97K
Dec 26, 2025	6.47	6.47	6.15	6.16	439.87K
Dec 24, 2025	6.45	6.56	6.40	6.50	239.53K
Dec 23, 2025	6.49	6.61	6.34	6.43	470.87K
Dec 22, 2025	6.54	6.75	6.47	6.59	583.87K
Dec 19, 2025	6.44	6.63	6.40	6.53	1.72M

Contact Details

San Diego, CA 92121

United States

https://arcturusrx.com 858 900 2660

About Company

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

Stock Peers

ARGX

9.63+1.20%

argenx SE$809.64 REGN

0.74+0.10%

Regeneron Pharmaceuticals, Inc.$733.78 MDGL

3.27+0.65%

Madrigal Pharmaceuticals, Inc.$504.95 UTHR

3.14+0.68%

United Therapeutics Corporation$468.07 VRTX

0.72+0.16%

Vertex Pharmaceuticals Incorporated$442.08 ALNY

-3.74-1.04%

Alnylam Pharmaceuticals, Inc.$355.53 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

6.83+2.15%

Praxis Precision Medicines, Inc.$324.08 KRYS

-10.23-3.59%

Krystal Biotech, Inc.$274.81 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) closed at $7.27 USD, gaining $0.17 (2.39%) from the previous close of $7.10. The stock is currently mid-range between its 52-week high and low $5.85 and $24.17. With a market capitalization of about $206.57 million, Arcturus Therapeutics Holdings Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.24). Key stats such as the average daily volume over the past year has been around 1.19 million shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Arcturus Therapeutics Holdings Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Joseph E. Payne, the company employs approximately 174 people and listed since May 22, 2013. Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 5.08%, SMA50 1.72%, SMA200 -43.59%). The stock’s 14-day RSI is 49.38 (neutral), while the ATR of 0.41 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -70.62% below its high and over 21.37% above its low. Average 10-day trading volume of 654.69 thousand shares is below the 3-month average of 1.19 million, indicating normal recent market interest.

Valuation Metrics

Arcturus Therapeutics Holdings Inc. trades at a P/E ratio of -2.94, slightly below the S&P 500 average, with a price-to-sales ratio of 2.23 and a price-to-book ratio of 0.87 suggesting the stock is closer to book value. The P/FCF stands at -3.5, also above market averages.

Dividend & Fair Value

Arcturus Therapeutics Holdings Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$26.43. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Arcturus Therapeutics Holdings Inc. generated EPS of -$2.46 over the past year. Five-year average earnings growth is -6.84%. Wall Street analysts project EPS growth of 19.31% annually over the next five years. The latest quarter delivered EPS of $0.12. The next quarter is forecast at -$0.79. Next year's EPS is expected at -$102.65. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 9 Buy ratings, 5 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $72.00 to $9.00. The high target offers 914.08% upside. The low target suggests 26.76% downside. The mean target is $40.55. This offers 471.13% upside. Arcturus Therapeutics Holdings Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 10, 2025, missed forecasts by -114.87%. The prior quarter beat by -69.37%. Over the last six quarters, Apple has recorded several small beats. These include -65.41% in August 05, 2024.

Shareholding & Insider Activity

Arcturus Therapeutics Holdings Inc. has 28.41 million shares outstanding. The public float is 26.27 million shares, elevated short interest at 38.03% of float. This equals 7.16 million shares. The short ratio is 10.11 days. Institutional investors hold 69.99% of the float. Insiders own 5.77%. Payne Joseph E holds 1.48 million shares, Ultragenyx Pharmaceutical Inc. has 1.40 million shares and SCHORSCH NICHOLAS S has 993.24 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Arcturus Therapeutics generated $157.75M in revenue, or $5.92 per share. Gross margin was 98.13%, operating margin -2.63%, and net profit margin -18.84%. Returns are negative, with ROA at -6.92% and ROE at -10.67%.
On valuation metrics, Arcturus Therapeutics trades at a P/E of -2.94, P/S of 2.23 and P/B of 0.87. The current ratio is 7.86 and quick ratio is 7.86. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -568.18 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.10, supported by a cash flow-to-debt ratio of -2.67.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Arcturus Therapeutics posted revenue of $157.75M, down slightly from $205.76M in the prior quarter. Gross profit was $154.79M (margin 98.13%). Operating income was - $4.15M (margin -2.6%). Net income was- $29.73M (EPS - $1.12).
The company ended the quarter with $347.01M in cash and short-term investments, a total debt of $30.22M, and net debt of - $316.79M. Total assets were $429.40M, with equity of $278.51M. Financials further reflected weakness, with operating cash flow of - $18.10M, free cash flow of - $21.00M, and capital expenditures of - $2.90M.

Price Forecast & Outlook

Our AI price prediction model suggests that Arcturus Therapeutics Holdings Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.7%, with price expected at $7.15 by February 03, 2026, within a range of $6.47 to $7.71 3-Month Outlook: Projected fall of -70.28%, reaching $2.11 by April 16, 2026, with a range of $1.39 to $2.71. 1-Year Outlook: Projected loss of -31.83%, with price at $4.84 by January 15, 2027, within a range of $0.00 to $1.68.

Key Takeaways

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shares are up 15.82% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Arcturus Therapeutics Holdings Inc. trading at a premium to the broader market with a P/E of -2.94. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $47.89, suggesting 574.51% upside. Our AI forecast model points to short-term strength (0.7% over two weeks), a medium-term fall (-70.28% over three months), and a longer-term loss (-31.83% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Arcturus Therapeutics Holdings Inc. (ARCT) stock price?

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) stock price is $7.27 in the last trading session. During the trading session, ARCT stock reached the peak price of $7.35 while $7.00 was the lowest point it dropped to. The percentage change in ARCT stock occurred in the recent session was 2.39% while the dollar amount for the price change in ARCT stock was $0.17.

ARCT's industry and sector of operation?

The NASDAQ listed ARCT is part of Biotechnology industry that operates in the broader Healthcare sector. Arcturus Therapeutics Holdings Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ARCT?

Mr. Keith C. Kummerfeld CPA
Senior Vice President of Fin. & Corporation Controller
Mr. Keith C. Kummerfeld C.P.A.
Senior Vice President of Fin. & Corporation Controller
Ms. Neda Safarzadeh
Vice President and Head of IR/PR & Marketing
Mr. Andrew H. Sassine MBA
Chief Financial Officer & Director
Mr. Lance Kurata
Chief Legal Officer
Mr. Deepankar Roy
Senior Director of Investor Relations
Dr. Padmanabh Chivukula
Founder, Chief Scientific Officer, Chief Operating Officer & Sec.
Mr. Kevin T. Skol
Chief Bus. Officer
Dr. Dushyant B. Varshney Ph.D.
Chief Technology Officer
Kyle Gutstadt
Senior Analyst of Investor & PR
Dr. Juergen Froehlich FCPh, M.D., MBA
Chief Medical Officer
Dr. Igor Smolenov M.D., Ph.D.
Chief Devel. Officer
Dr. Steven George Hughes M.B.A., M.D.
Chief Medical Officer
Mr. Joseph E. Payne M.Sc.
Founder, Pres, Chief Executive Officer & Director

How ARCT did perform over past 52-week?

ARCT's closing price is 21.37% higher than its 52-week low of $5.85 where as its distance from 52-week high of $24.17 is -70.62%.

How many employees does ARCT have?

Number of ARCT employees currently stands at 174.

Link for ARCT official website?

Official Website of ARCT is: https://arcturusrx.com

How do I contact ARCT?

ARCT could be contacted at phone 858 900 2660 and can also be accessed through its website. ARCT operates from 10628 Science Center Drive, San Diego, CA 92121, United States.

How many shares of ARCT are traded daily?

ARCT stock volume for the day was 342.66K shares. The average number of ARCT shares traded daily for last 3 months was 1.19M.

What is the market cap of ARCT currently?

The market value of ARCT currently stands at $206.57M with its latest stock price at $7.27 and 28.41M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	174
Beta	2.24
Sales or Revenue	$157.75M
5Y Sales Change%	2.787%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ARCT Company Profile and Key Details

Arcturus Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways